1. A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine
- Author
-
Paolo Martelletti, Biagio Panascia, Brigida Fierro, Patrizia Santoro, Carlo Lisotto, Stefano Omboni, Maria Adele Giamberardino, Lidia Savi, D. Moscato, Giorgio Zanchin, Marco Bartolini, Michel D. Ferrari, Filippo Brighina, Grazia Sances, Luigi Alberto Pini, Bartolini, M, Giamberardino, MA, Lisotto, C, Martelletti, P, Moscato, D, Ganascia, B, Savi, L, Pini, LA, Sances, G, Santoro, P, Zanchin, G, Omboni, S, Ferrari, MD, Brighina, F, and Fierro, B
- Subjects
Adult ,Male ,Adolescent ,Original ,Migraine with Aura ,Population ,Almotriptan ,Carbazoles ,Clinical Neurology ,Migraine ,almotriptan ,Frovatriptan ,Young Adult ,frovatriptan ,migraine ,patient preference ,Double-Blind Method ,medicine ,Humans ,Migraine, Frovatriptan, Almotriptan, Patient preference ,Patient preference ,education ,Aged ,education.field_of_study ,Cross-Over Studies ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Crossover study ,Rizatriptan ,Tryptamines ,Migraine with aura ,Serotonin Receptor Agonists ,Treatment Outcome ,Anesthesiology and Pain Medicine ,Italy ,Tolerability ,Anesthesia ,Acute Disease ,Female ,Settore MED/26 - Neurologia ,Neurology (clinical) ,medicine.symptom ,business ,medicine.drug - Abstract
The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1–3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting
- Published
- 2011